Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023

Dyne Therapeutics, Inc.

2023-Q2 EPS reported -$1.88

Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.
R&D expenses $59.1M, up from $46.7M; G&A $7.6M vs $6.1M.
Cash and securities $207.7M as of June 30, 2023; funds operations through 2024.
Enrollment ongoing in ACHIEVE (DYNE-101, DM1) and DELIVER (DYNE-251, DMD) registrational trials; initial data expected H2 2023.
EMA granted orphan drug designation for DYNE-101 in DM1; FORCE platform CNS delivery data at ASGCT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dyne Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $64.9 million, EPS $1.08 per basic and diluted share.

Period: the quarter ended June 30, 2023
Net income: $64.9 million
EPS: $1.08 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the quarter ended June 30, 2023 was $64.9 million, or $1.08 per basic and diluted share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.